

REMARKS

By this amendment, claims 1, 3, 4, 5 and 9 have been amended, claims 10 and 11 have been added, and claims 2 and 8 have been cancelled without prejudice. Claims 1, 3-7, and 9-11 are thus currently under examination in the present application. For the reasons set forth below, Applicants submit that the present amendments and arguments place this application in condition for immediate allowance.

As an initial matter, with regard to new claims 10 and 11, these claims have been added to incorporate alternative dependencies that were initially presented in claim 5 of the application, as filed. Accordingly, no new matter has been added by these amendments.

In the Office Action of June 24, 2008, the Examiner first objected to claim 4 for not having a period at the end of the claim. This objection has now been rendered moot by the present amendment which inserts a period at the end of claim 4, and thus the objection should be withdrawn.

In the Office Action, the Examiner then made various rejections to claims 1-9 under 35 U.S.C. §112, second paragraph as being indefinite. In particular, the Examiner asserted that certain terms and phrases in claims 1, 2, and 9 were unclear. Each of these rejections is addressed in detail below and, accordingly, for the reasons set forth below, Applicants submit that the Examiner's rejections are respectfully traversed and should be withdrawn.

With regard to the Examiner's rejection of claim 1 under 35 U.S.C. §112, second paragraph, the Examiner has asserted that the complete structure of the hapten is unclear in terms of both the moieties attached to the hapten and the linkage position of the carrier protein, and, further, that it is unclear how the $\text{CH}_3\text{O}-\text{C}(\text{CH}_3)_2-\text{CH}_2$ moiety is attached to the carrier molecule. These assertions have now become moot by virtue of the present amendments to claim 1. Specifically, by virtue of the present amendments, Applicants have amended claim 1 to incorporate the limitation previously found in claim 2 indicating that the "hapten is: $\text{CH}_3\text{O}-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{X}-\text{B}$ where X is a spacer and B is a group capable of binding to a carrier protein..." As such, claim 1 now provides a complete structure of the hapten and thus clearly indicates the particular moieties that comprise the hapten molecule as well as the linkage position of the carrier protein. Further, by the present amendments to claim 1, "B" is indicated as "a group capable of binding to a carrier protein" and thus particularly points out how the hapten is conjugated to a carrier protein.

With regard to the Examiner's rejection of claim 2 under 35 U.S.C. §112, second paragraph, the Examiner asserted that the terms "spacer" and "group capable of binding to a carrier protein" were indefinite and thus it was unclear what compounds or groups were encompassed by these terms. By the present amendments, these terms no longer appear in claim 2 due to the cancellation of claim 2, but are instead are recited in claim 1. Nevertheless, contrary to the Examiner's assertions, both of these terms are routinely used in the art to identify various mechanisms for suitably conjugating a portion of a hapten and, thus comply with the requirements of 35 U.S.C. §112, second paragraph.

Indeed, a quick database search of the phrase "hapten conjugation spacer" uncovered over 18,000 references showing that the term "spacer" is widely used in the art in relation to haptens. For example, the attached abstract of Yoo, et al., which was uncovered in the search, recites that "five haptens of fenthion differing in spacer arm length (4-8 atoms) were synthesized and...conjugated to bovine serum albumin and keyhole limpet hemocyanin to be used as immunogens" Further, the attached abstract of Ungar-Waron is directed toward the "Role of a rigid polyproline spacer inserted between hapten carrier in the induction of anti-hapten antibodies and delayed hypersensitivity." As yet another example of the use of the term "spacer" when referring to haptens, the attached abstract of "Shinkaruk, et al., which was also uncovered in the search discussed above, begins with "[t]wo carboxylic acid haptens of glycitein were synthesized, with a spacer arm at the C2 position. They differed in the length of the spacer arm, with the length of the spacer arms being three or four carbon atoms" and further recites that "...specificity is not determined by the length of the spacer arm."

Furthermore, U.S. Patent No. 5,219,764 to Huber, et al. refers in its abstract to "Hapten-biotin conjugates in which the hapten is linked with biotin via a spacer, which has 26 to 40 atoms in its chain..." It is further noted that claim 1 of the Huber, et al. reference includes precisely the same wording, without any limitations on what is meant by the term "spacer." Indeed, column 3, lines 19-24 of the Huber, et al. reference merely indicates that "[t]he production of the conjugates...can either take place by reacting the hapten and the biotin with a bi-functional spacer molecule in which functional groups present on the hapten and in the biotin molecule react with the functional groups of the

spacer molecule.” As one of ordinary skill in the art would further recognize, these general references to “functional groups of the spacer molecule” are precisely what is being referred to in the present application by the use of the phrase “group capable of binding to a carrier protein.”

Accordingly, in light of the foregoing discussion of the use of the term “spacer” and the phrase “group capable of binding to a carrier protein” in the various references cited above, it is thus clear that these terms are routinely used in the art when referring to haptens and thus create no indefinite issues whatsoever.

With regard to the Examiner’s rejection of claim 9 under 35 U.S.C. §112, second paragraph, the Examiner asserted that claim 9 is indefinite because it does not recite any positive steps for a method of assaying a sample for fuel oxygenates. Contrary to the Examiner’s assertions, however, claim 9 is a proper method claim which recites positive steps. Claim 9 is directed to a method for assaying a sample for fuel oxygenates that not only comprises generating antibodies according to the method of claim 1, but further comprises the step of carrying out an immunoassay using the antibodies. As such, claim 9 recites a method which is comprised of at least eight steps, namely the seven steps recited in claim 1 together with the step of “carrying out an immunoassay using said antibodies” and thus cannot be fairly characterized as being indefinite for reciting a method that does not set forth any steps. In this regard, it is also further noted that the phrase “an immunoassay using antibodies” is well known in the art, and thus it would not be necessary to further clarify the additional steps that are involved in carrying out such an immunoassay.

In any event, in order to eliminate any objection on this point, Applicants have amended Claim 9 so that the word “and” has been replaced by “further comprising” which Applicants submit has the same meaning and scope of the prior language.

In light of the discussion above, Applicants thus submit that the claims of the present application are in compliance with 35 U.S.C. §112, second paragraph. Accordingly, Applicants respectfully submit that the Examiner’s rejection under 35 U.S.C. §112, second paragraph is respectfully traversed and should be withdrawn.


In the Office Action of June 24, 2008, the Examiner further rejected claim 9 under 35 U.S.C. §101 because the claimed recitation of a use, without setting forth any steps involved in the process, was an improper definition of a process. As discussed above, however, in relation to the Examiner rejection of claim 9 pursuant to 35 U.S.C. §112, second paragraph, Claim 9 recites a method which is comprised of at least eight steps, the seven steps recited in claim 1 together with the step of “carrying out an immunoassay using said antibodies.” Further, Applicants have amended Claim 9 so that the word “and” has been replaced by “further comprising”. As such, Applicants respectfully submit that claim 9 is a proper process claim under 35 U.S.C. §101 and, consequently, that the Examiner’s rejection is respectfully traversed and should be withdrawn.

Finally, in the Office Action, the Examiner rejected claim 8 under 35 U.S.C. §102(e) as being anticipated by or, in the alternative, under 35 U.S.C. §103 as being obvious over Pourfarzaneh (U.S. Pat. No. 6,416,671). Without addressing the merits of this rejection, this rejection has now become moot by virtue of the present amendments cancelling claim 8 and, accordingly, the Examiner’s rejection should be withdrawn.

In light of the amendments and arguments provided herewith, Applicants submit that the present application overcomes all prior rejections and objections, and has been placed in condition for allowance. Such action is respectfully requested.

Respectfully submitted,

Date: February 2, 2008



By: B. Aaron Schulman
Registration No.: 31,877

STITES & HARBISON PLLC ♦ 1199 North Fairfax St ♦ Suite 900 ♦ Alexandria, VA 22314
TEL: 703-739-4900 ♦ FAX: 703-739-9577 ♦ CUSTOMER NO. 000881

[My Cart](#) [My Profile](#) [Log In](#) [Athens Log In](#)[Home](#) / [Medical, Veterinary and Health Sciences](#) / [Immunology](#)

This journal provides **OnlineOpen** access for individual articles

>> Click the [OnlineOpen](#) link below for more information.

**European Journal of Immunology**

Volume 35 Issue 4, Pages 201 - 205

Published Online: 22 Nov 2005

Copyright © 2005 WILEY-VCH Verlag GmbH
& Co. KGaA, Weinheim

- [Get Sample Copy](#)
- [Recommend to Your Librarian](#)
- [Save journal to My Profile](#)
- [Set E-Mail Alert](#)
- [Email this page](#)
- [Print this page](#)
- [RSS web feed \(What is RSS?\)](#)

An official Journal of

efis[Go to Society Site](#)[Save Article to My Profile](#) [Download Citation](#)[< Previous Abstract](#) | [Next Abstract >](#)[Abstract](#) | [References](#) | [Full Text: PDF \(Size: 481K\)](#) | [Related Articles](#) | [Citation Tracking](#)**Article****Role of a rigid polyproline spacer inserted between hapten and carrier in the induction of anti-hapten antibodies and delayed hypersensitivity**

Hana Ungar-Waron, Dalia Gurari, Esther Hurwitz, M. Sela *

Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot

*Correspondence to: M. Sela, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel

Funded by:

- United States Public Health Service, Bethesda, Maryland
- National Institutes of Health

ABSTRACT

The synthesis and characterization are described of a hapten-protein conjugate in which carrier [BSA or the synthetic multichain polymer, poly-L-(Tyr, Glu)-poly-DL-Ala-poly-L-Lys, (T,G)-A-L] and hapten 2,4-dinitrophenyl (DNP) are separated by the rigid peptide chain of an L-proline oligomer. This compound has been used to study the carrier effect in an attempt to distinguish between the cooperation and local environment theories which have been put forward to explain it.

Rabbits were given a primary injection of the antigen DNP-poly-L-prolyl-BSA (bovine serum albumin). The secondary response was followed *in vitro* after stimulation with antigens composed of hapten coupled to carriers in the presence or absence of a polyproline spacer, and compared to secondary stimulation with the homologous antigen. Antibody production was monitored by thymidine incorporation, by inactivation of modified bacteriophage and by hemolytic plaque formation. Experiments in delayed hypersensitivity were also carried out using the same antigens. In both systems it was found that the insertion of the inflexible spacer molecule between hapten and carrier did not abolish the carrier effect. These results lend support to the cooperation hypothesis as explanation of the carrier effect.

Received: 7 November 1972


DIGITAL OBJECT IDENTIFIER (DOI)

10.1002/eji.1830030405 About DOI

Related Articles

- Find other articles like this in Wiley InterScience
- Find articles in Wiley InterScience written by any of the authors


Wiley InterScience is a member of CrossRef.



Request Reprint

Copyright © 1999-2009 John Wiley & Sons, Inc. All Rights Reserved.

A service of the U.S. National Library of Medicine
and the National Institutes of Health


My NCBI 
[\[Sign In\]](#) [\[Register\]](#)

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search: PubMed  for   Advanced Search

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Note: Performing your original search, *haptén conjugation spacer*, in PubMed will retrieve **8 records**.

Display [AbstractPlus](#)  Show [20](#)  Sort By  Send to 
[All: 1](#) [Review: 0](#)

 1: 1 Agric Food Chem. 2008 Aug 27;56(16):6809-17. Epub 2008 Jul 23.



[Links](#)

Synthesis of haptens and conjugates for ELISA of glycetin: development and validation of an immunological test.

Shinkaruk S, Lamothe V, Schmitter JM, Fructus A, Sauvart P, Vergne S, Degueil M, Babin P, Bennetau B, Bennetau-Pelissero C.

Université de Bordeaux, EA 2975 UBX1-UBX2-ENITA de Bordeaux, F-33405, France.

Two carboxylic acid haptens of glycetin were synthesized, with a spacer arm at the C2 position. They differed in the length of the spacer arm, with the length of the spacer arms being three or four carbon atoms, and were named Delta3-glycetin and Delta4-glycetin haptens, respectively. The different haptens were coupled to bovine serum albumin (BSA), and the coupling efficiency was assessed by MALDI mass spectrometry. Polyclonal antibodies were generated against the BSA conjugates. An additional conjugate of Delta4-glycetin hapten was generated with swine thyroglobulin (Thyr). Enzyme-linked immunosorbent assays (ELISAs) based on the competition between free glycetin and Delta4-glycetin-Thyr conjugates for specific antibodies were developed. The IC50 of the standard curves was 15.6 ng mL⁻¹ with anti-Delta3-glycetin and 62.5 ng mL⁻¹ with anti-Delta4-glycetin, that is, 10.9 and 44 pmol/well, respectively. With the Delta3-glycetin antibody, interassay and intra-assay variations were 12.2 and 11.5%, respectively. Specificity tests did not show any significant cross-reaction with any other soy isoflavone. This specificity is not influenced by the length of the spacer arm. The assay was validated by measurements performed on plasma samples as well as on soy-based foodstuffs and on soy-based food supplements.

PMID: 18646854 (PubMed - indexed for MEDLINE)

Related Articles

Synthesis of haptens and conjugates for ELISAs of phytoestrogens. Development of the *haptén conjugation spacer* [J Agric Food Chem. 2008]

Preparation and characterization of domoic acid-protein conjugates using small amount of toxin in a reversed micellar medium: application in a competitive enzyme-linked immunosorbent assay. [Biol Conjug Chem. 1999]

Hapten heterology for a specific and sensitive indirect enzyme-linked immunosorbent assay for organophosphorus insecticide fenitrothion. [Anal Chim Acta. 2007]

Review The effects of soy isoflavones on obesity [Exp Biol Med (Maywood). 2008]

Review The key importance of soy isoflavone bioavailability to understanding health benefits [Crit Rev Food Sci Nutr. 2008]

[» See Reviews...](#) [» See All...](#)

Patient Drug Information





Estrogen (Cenestin®, Enjuvia®, Estrace®, ...) Estrogen is used to treat hot flashes ('hot flashes'; sudden strong feelings of heat and sweating) in women who are experiencing menopause ('change of life', the end of monthly menstrual periods). Some brands of estrogen...

[» read more...](#)

Recent Activity

[Turn Off](#) [Clear](#)

Synthesis of haptens and conjugates for ELISA of glycetin: development and validation of ...


Display [AbstractPlus](#)  Show [20](#)  Sort By  Send to 

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



Titre du document / Document title

Synthesis of haptens for immunoassay of organophosphorus pesticides and effect of heterology in hapten spacer arm length on immunoassay sensitivity

Auteur(s) / Author(s)

YOO JUNG KIM ⁽¹⁾ ; YOUNG AE CHO ⁽²⁾ ; LEE Hye-Sung ⁽²⁾ ; YONG TAE LEE ⁽¹⁾ ; GEE Shirley J. ⁽³⁾ ; HAMMOCK Bruce D. ⁽³⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Department of Biochemistry, Yeungnam University, Gyongsan 712-749, COREE, REPUBLIQUE DE

⁽²⁾ Department of Food Science and Nutrition, Kyungpook National University, Daegu 702-701, COREE, REPUBLIQUE DE

⁽³⁾ Department of Entomology and Cancer Research Center University of California, Davis, CA 95616, ETATS-UNIS

Résumé / Abstract

The synthetic method for haptens of organophosphorus (OP) pesticides with a spacer arm (amino carboxylic acid) attached at the pesticide thiophosphate group was simplified to a large extent. While the previous synthetic approach for this type of haptens requires seven steps, the present process involves only two steps. Using this process, five haptens of fenthion differing in spacer arm length (4-8 atoms) were synthesized and they were conjugated to bovine serum albumin and keyhole limpet hemocyanin to be used as immunogens. Rabbits were immunized with these hapten-protein conjugates for production of polyclonal antibodies against fenthion. The five haptens were conjugated to ovalbumin to be used as plate-coating antigens and twenty polyclonal antisera to the haptens were screened against each of the five coating antigens using noncompetitive and competitive indirect enzyme-linked immunosorbent assay (ELISA). The titer difference between the homologous and heterologous combinations was small, suggesting that heterology in spacer arm length is not important for the antigen recognition by antibodies. While the heterology in spacer length of the coating antigen had no significant effect on the sensitivity of ELISA, heterology in spacer structure of the coating antigen produced a remarkable improvement in the sensitivity of ELISA.

Revue / Journal Title

Analytica chimica acta ISSN 0003-2670 CODEN ACACAM

Source / Source

2003, vol. 475, n°1-2, pp. 85-96 [12 page(s) (article)] (28 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier, Amsterdam, PAYS-BAS (1947) (Revue)

Mots-clés anglais / English Keywords

Toxicology ; ELISA assay ; Hapten protein conjugate ; Enzyme immunoassay ; Biological fluid ; Fenthion ; Organophosphorus compounds ; Pesticides ; Quantitative analysis ; Multicomponent analysis ; Biochemical analysis ;

Mots-clés français / French Keywords

Toxicologie ; Technique ELISA ; Conjugué haptène protéine ; Méthode immunoenzymatique ; Liquide biologique ; Fenthion ; Organophosphoré ; Pesticide ; Analyse quantitative ; Analyse multitélément ; Analyse biochimique ;

Mots-clés espagnols / Spanish Keywords

Toxicología ; Técnica ELISA ; Conjugado hapteno proteína ; Método inmunoenzimático ; Líquido biológico ; Fentión ; Organofosforado ; Plaguicida ; Análisis cuantitativo ; Análisis multielemento ; Análisis bioquímico ;

Mots-clés d'auteur / Author Keywords

Organophosphorus pesticide ; Hapten synthesis ; Spacer arm ; Fenthion ; Enzyme-linked immunosorbent assay ; ELISA ;

Localisation / Location

INIST-CNRS, Cote INIST : 3950, 35400011977064.0090

Copyright 2008 INIST-CNRS. All rights reserved

Toute reproduction ou diffusion même partielle, par quelque procédé ou sur tout support que ce soit, ne pourra être faite sans l'accord préalable écrit de l'INIST-CNRS.

No part of these records may be reproduced or distributed, in any form or by any means, without the prior written permission of INIST-CNRS.

N° notice refdoc (ud4) : 15231427

Rechercher dans CAT.INIST / Search in CAT.INIST

Google Custom Search



US005219764A

United States Patent [19]
Huber et al.[11] **Patent Number:** **5,219,764**
[45] **Date of Patent:** **Jun. 15, 1993**[54] **HAPTEN-BIOTIN CONJUGATES AND
THEIR USE**[75] **Inventors:** Erasmus Huber, Unterfinning;
Dietmar Zdunek, Munich; Christian
Klein; Roland Schenk, both of
Weilheim, all of Fed. Rep. of
Germany[73] **Assignee:** Boehringer Mannheim GmbH,
Mannheim, Fed. Rep. of Germany[21] **Appl. No.:** 683,284[22] **Filed:** Apr. 10, 1991[30] **Foreign Application Priority Data**

Apr. 10, 1990 [DE] Fed. Rep. of Germany 4011601

[51] **Int. Cl.⁵** G01N 33/536; G01N 33/541;
C07D 495/04[52] **U.S. Cl.** 436/536; 436/500;
436/540; 436/544; 435/7.5; 548/304.1;
544/267; 562/447[58] **Field of Search** 435/7.5; 436/536, 500,
436/532, 533, 540, 543, 544, 822, 823; 530/367,
380, 402, 807; 548/303; 544/267; 562/447[56] **References Cited****U.S. PATENT DOCUMENTS**4,617,261 10/1986 Sheldon, III et al. 435/6
4,760,142 2/1988 Primes et al. 544/287
4,898,951 2/1990 Symons 548/303**FOREIGN PATENT DOCUMENTS**0183901 11/1986 European Pat. Off. .
0310361 5/1989 European Pat. Off. .
0315317 10/1989 European Pat. Off. .
0349988 10/1990 European Pat. Off. .**OTHER PUBLICATIONS**Green et al *Biochem J.* (1971) 125, 781-791.
Harlow et al Chapter 14, pp. 591-592 in *Antibodies A
Laboratory Manual* Cold Spring Harbor (1988).*Primary Examiner*—Esther L. Kepplinger*Assistant Examiner*—Lora M. Green*Attorney, Agent, or Firm*—Felfe & Lynch[57] **ABSTRACT**

Hapten-biotin conjugates in which the hapten is linked
with biotin via a spacer, which has 26 to 40 atoms in its
chain and contains at least 5 heteroatoms, are novel and
are suitable, in particular for use in a competitive homo-
geneous immunoassay in which the agglutination which
occurs in the reaction is evaluated by turbidimetric or
nephelometric measurements.

6 Claims, No Drawings